Active	Status	Sponsor type	Region	Phase	Filter
5 Active 17 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
OLX101 / OliX Pharma
NCT04012099: the Hypertrophic Scar Prevention of BMT101.	Terminated	2a	20	RoW	BMT101, cp-asiRNA	Hugel	Hypertrophic Scar	05/23	05/23
NCT04877756: Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery	Completed	2	22	US	OLX10010, a cell penetrating asymmetric small interference RNA (cp-asiRNA), targeting a gene involved in formation of fibrosis	Olix Pharmaceuticals, Inc., Alira Health	Hypertrophic Scar	01/23	07/23
Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
2018-003983-30: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESS III)	Not yet recruiting	3	353	Europe	BoNT/A-DP, Lyophilisate for solution for injection, Botulax	Croma-Pharma GmbH, CROMA-PHARMA GmbH	Moderate to severe glabellar lines, Moderate to severe glabellar lines, Body processes [G] - Biological Phenomena [G16]
2019-003481-41: Study to compare the efficacy, time to onset, and duration of effect of Botulinum Type A Toxins in the treatment of glabellar frown lines	Not yet recruiting	2	200	Europe	BoNT/A-DP, BOTOX Cosmetic, onabotulinumtoxinA, Lyophilisate for solution for injection, Botulax, BOTOX Cosmetic	Croma-Pharma GmbH, Croma-PHARMA GmbH	moderate to severe glabellar frown lines at maximum frown, Moderate to severe glabellar lines, Body processes [G] - Biological Phenomena [G16]
botulinum toxin type A (HG-102) / Hugel
NCT05801146: Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines	Recruiting	3	272	RoW	Botulinum Toxin Type A Injection [HG102], HG102, Botulinum Toxin Type A Injection [Botox], Botox®	Hugel	Glabellar Lines	03/25	10/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
OLX101 / OliX Pharma
NCT04012099: the Hypertrophic Scar Prevention of BMT101.	Terminated	2a	20	RoW	BMT101, cp-asiRNA	Hugel	Hypertrophic Scar	05/23	05/23
NCT04877756: Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery	Completed	2	22	US	OLX10010, a cell penetrating asymmetric small interference RNA (cp-asiRNA), targeting a gene involved in formation of fibrosis	Olix Pharmaceuticals, Inc., Alira Health	Hypertrophic Scar	01/23	07/23
Letybo (letibotulinumtoxinA-wlbg) / Hugel, Croma Pharma
2018-003983-30: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESS III)	Not yet recruiting	3	353	Europe	BoNT/A-DP, Lyophilisate for solution for injection, Botulax	Croma-Pharma GmbH, CROMA-PHARMA GmbH	Moderate to severe glabellar lines, Moderate to severe glabellar lines, Body processes [G] - Biological Phenomena [G16]
2019-003481-41: Study to compare the efficacy, time to onset, and duration of effect of Botulinum Type A Toxins in the treatment of glabellar frown lines	Not yet recruiting	2	200	Europe	BoNT/A-DP, BOTOX Cosmetic, onabotulinumtoxinA, Lyophilisate for solution for injection, Botulax, BOTOX Cosmetic	Croma-Pharma GmbH, Croma-PHARMA GmbH	moderate to severe glabellar frown lines at maximum frown, Moderate to severe glabellar lines, Body processes [G] - Biological Phenomena [G16]
botulinum toxin type A (HG-102) / Hugel
NCT05801146: Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines	Recruiting	3	272	RoW	Botulinum Toxin Type A Injection [HG102], HG102, Botulinum Toxin Type A Injection [Botox], Botox®	Hugel	Glabellar Lines	03/25	10/25